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Re: ‘Efﬁcacy and Safety of the New Oral Anticoagulants
Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the
Treatment and Secondary Prevention of Venous
Thromboembolism: A Systematic Review and Meta-
analysis of Phase III Trials’d Key Learning Points for
Surgeons
We read with great interest the timely systemic review and
meta-analysis by Kakkos et al. on the efﬁcacy and safety of
the new oral anticoagulants (NOACs).1 With increasing
numbers of surgical patients receiving anticoagulant medi-
cations, it is imperative for surgeons to be aware of the
therapeutic treatments available.Table 1. Comparison of novel anticoagulants: mode of action and i
Dabigatran Rivaroxiban
Class Direct thrombin (IIa)
inhibitor
Factor Xa inhibito
Mode of action Direct, competitive
inhibition of free and clot-
bound thrombin
Direct inhibition o
factor Xa and fact
bound to prothro
complex
Indication/licence
(bold)
Stroke prevention in
patients with atrial
ﬁbrillation D one of
reduced ejection fraction/
CHD/diabetes/< 65
(150 mg twice daily)
Treatment of DVT or PE
after parenteral
anticoagulation for 5e10 d
Prevention of venous
thromboembolism in
elective hip/knee surgery
(110 mg 1e4 h after
surgery, then 220 mg once
daily 9/7)
Prevention of
atherothrombotic
adults after acute
syndrome (2.5 mg
Prevention of ven
thromboembolism
elective hip/knee
(10 mg)
Stroke prevention
patients with atri
ﬁbrillation D one
risk factor (20 mg
Treatment of DVT
(15 mg twice dail
prophylaxis after
DVT/PE (20 mg o
Dosage 110e220 mg 2.5e20.0 mg
Reversal Speciﬁc reversal not
available. Consider
prothrombin complex
concentrate or dialysis
Speciﬁc reversal n
available. Conside
prothrombin com
concentrate in em
setting
Monitoring No routine monitoring
required
No routine monit
required
Periprocedural
management
Dependent on renal
function:
CrCL >80: stop 24e48 h
before
CrCL 51e80: stop 48e72 h
before
CrCL 30e50: stop 72e96 h
before
Stop at least 24 h
intervention
Note. CHD ¼ coronary heart disease; DVT ¼ deep vein thrombosisOver the last 5 years new oral anticoagulants such as
dabigatran, rivaroxiban, apixiban, and edoxaban have been
used within the clinical setting. The advantages of using
NOACs include their short half-lives and rapid onset of ac-
tion, they can be discontinued and resumed rapidly in the
pre-/postoperative period, and their use decreases the
window of risk for thromboembolism. Several landmark
studies (EINSTEINePE, AMPLIFY, RE-COVER) have shown
there to be no inferiority in their clinical use compared with
standard therapy.2e4
With such valued beneﬁts the NOACs are here to stay; it
is therefore imperative for surgeons to appreciate their ef-
ﬁcacy, safety, and clinical use. For ease, these are summa-
rized Table 1.ndication for use.
Apixaban Edoxaban
r Factor Xa inhibitor d
f free
or Xa
mbinase
Direct inhibition of free
and clot-bound factor Xa
Direct inhibitor of factor Xa
events in
coronary
)
ous
in
surgery
in
al
CHADS
)
and PE
y), or
recurrent
nce daily)
Prevention of venous
thromboembolism in
elective hip/knee surgery
(2.5 mg)
Stroke prevention in
patients with atrial
ﬁbrillation D one CHADS
risk factor (5 mg)
Treatment of DVT or PE and
prevention of recurrence of
symptomatic venous
thromboembolism
Prevention of stroke and
systemic embolic events in
patients with atrial
ﬁbrillation
No current UK licence
2.5e5.0 mg ? 30.0e60.0 mg
ot
r
plex
ergency
Speciﬁc reversal not
available. Consider
prothrombin complex
concentrate in emergency
setting
Speciﬁc reversal not
available. Consider
prothrombin complex
concentrate in emergency
setting
oring No routine monitoring
required
No routine monitoring
required
prior to Stop at least 24 h prior to
intervention
Half-life similar to
rivaroxiban and apixaban
but no trial data on
periprocedural
management
; PE ¼ pulmonary embolism; CrCL ¼ creatinine clearance.
making a table to compare these novel anticoagulants in terms
of mode of action and indication for use. We would like to
point out that for the treatment of venous thromboembolism
the recommended dose of rivaroxaban is 20 mg OD after the
ﬁrst 3 weeks of treatment. Similarly for apixaban, currently
approved to treat venous thromboembolism in the European
Union, the therapeutic dose is 5mgBD (10mgBD for theﬁrst 7
days). Continuous medical education is obviously extremely
important for all physicians and part of this is accomplished by
attending educational seminars and conferences run by pro-
fessional societies like I.S.E.T.A.T. (Institute For The Study And
Education On Thrombosis And Antithrombotic Therapy,
http://www.imetha.gr/EN/) in our country.
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We would like to thank the authors of this letter for giving
us the opportunity to discuss some practical issues on the
use of NOAs in the management of VTE, which were not the
subject of our meta-analysis.1
We fully agree with the statement regarding the short
half-life and rapid onset of action of NOAs, which can be
discontinued and resumed rapidly pre- and post-operatively
for elective procedures, and that their use shortens the
window of risk for thromboembolism in patients treated for
either atrial ﬁbrillation or venous thromboembolism. These
are scenarios that are faced everyday in clinical practice; the
appropriate solution can be provided if the pharmacological
properties of the various NOAs are known.
We mentioned in the discussion section of our meta-
analysis the “different pharmacological properties, pharma-
codynamics, anticoagulation intensity, and dosing schedules of
the various agents.” These are recognized issues and the ﬁrst
two are the result of the different molecular structure of the
various NOAs. We would like to congratulate the authors for
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j.ejvs.2015.02.022
Response to Correspondence by de Borst re: ‘The True Risk
of Early Recurrent Stroke: Importance of Cohort
Composition and Index Event Deﬁnition’
We read with interest the invited commentary of de Borst1
in response to our recent article on the risk of early
recurrent stroke in a population with symptomatic carotid
stenosis, and would like to take the opportunity to clarify a
few points.2
De Borst argues that we underestimate the actual risk
of recurrent stroke by deﬁning the index event as the
event that resulted in referral to hospital. We consider
that the alternative, to deﬁne the index event as the very
ﬁrst neurological event would risk overestimating the rate
of recurrence because the calculation/estimation/assess-
ment will not include all patients with an event without
neurological recurrence, who do not seek medical atten-
tion. Therefore, it is our view that a valid recurrence rate
can only be calculated from events occurring after a
